$-0.20 EPS Expected for Intersect ENT Inc (XENT)

October 13, 2017 - By Winifred Garcia

 $ 0.20 EPS Expected for Intersect ENT Inc (XENT)

Analysts await Intersect ENT Inc (NASDAQ:XENT) to report earnings on November, 1. They expect $-0.20 EPS, up 9.09 % or $0.02 from last year’s $-0.22 per share. After $-0.08 actual EPS reported by Intersect ENT Inc for the previous quarter, Wall Street now forecasts 150.00 % negative EPS growth. The stock increased 1.97% or $0.55 during the last trading session, reaching $28.4. About 197,912 shares traded. Intersect ENT Inc (NASDAQ:XENT) has risen 79.98% since October 14, 2016 and is uptrending. It has outperformed by 63.28% the S&P500.

Intersect ENT Inc (NASDAQ:XENT) Ratings Coverage

Among 8 analysts covering Intersect ENT (NASDAQ:XENT), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Intersect ENT had 15 analyst reports since August 17, 2015 according to SRatingsIntel. The firm has “Buy” rating by Bank of America given on Friday, December 18. The rating was maintained by Canaccord Genuity with “Buy” on Wednesday, September 13. Northland Capital initiated the stock with “Outperform” rating in Tuesday, March 29 report. The firm has “Hold” rating by Northland Capital given on Wednesday, August 2. On Wednesday, November 2 the stock rating was downgraded by JP Morgan to “Neutral”. The stock of Intersect ENT Inc (NASDAQ:XENT) has “Buy” rating given on Thursday, October 1 by Canaccord Genuity. The company was maintained on Monday, August 17 by Canaccord Genuity. The stock of Intersect ENT Inc (NASDAQ:XENT) has “Hold” rating given on Thursday, October 6 by Deutsche Bank. The stock has “Buy” rating by Piper Jaffray on Monday, August 21. Deutsche Bank maintained Intersect ENT Inc (NASDAQ:XENT) on Wednesday, August 2 with “Buy” rating.

Intersect ENT, Inc. is a commercial-stage drug-device company. The company has market cap of $828.98 million. The Firm develops drugs for patients with ear, nose and throat conditions. It currently has negative earnings. The Firm has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents.

More notable recent Intersect ENT Inc (NASDAQ:XENT) news were published by: Seekingalpha.com which released: “Intersect Looks To Boost Position In ENT Implant Market, Driving Stock Up” on July 29, 2017, also Businesswire.com with their article: “Intersect ENT Announces Presentation of a Meta-Analysis From Two Randomized …” published on September 09, 2017, Businesswire.com published: “Intersect ENT Announces Presentation of Results from RESOLVE II, a Pivotal …” on October 08, 2017. More interesting news about Intersect ENT Inc (NASDAQ:XENT) were released by: Businesswire.com and their article: “Intersect ENT Announces PDUFA Date for Office-Based SINUVAâ„¢ Steroid Releasing …” published on May 22, 2017 as well as Fool.com‘s news article titled: “Why Intersect ENT Shares Are Rallying 17% Today” with publication date: May 03, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com